| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в грудні 2006 (uk)
- im Dezember 2006 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu n'avientu de 2006 (ast)
- scientific article published on 03 December 2006 (en)
|
| publication date
| |
| publication date
| |
| author name string
| |
| author name string
| - John Hunter
- Deen Tulshian
- William J Greenlee
- Ennio Ongini
- Jean Lachowicz
- Angela Monopoli
- Jinsong Hao
- Carolyn Foster
- Leyla Arik
- Andrew W Stamford
- Bernard R Neustadt
- Kwokei Ng
- Kung-I Feng
- Neil Lindo
|
| rdfs:label
| - Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines (en)
- Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines (nl)
|
| skos:prefLabel
| - Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines (en)
- Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines (nl)
|
| name
| - Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines (en)
- Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines (nl)
|
| author
| |
| author
| |
| title
| |
| title
| - Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.1016/J.BMCL.2006.11.083
|
| is about
of | |
| is cites work
of | - Adenosine A(2A) receptors in Parkinson's disease treatment
- Biophysical mapping of the adenosine A2A receptor
- Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists
- Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.
- Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued
- Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease
- Systemic inflammation regulates microglial responses to tissue damage in vivo
- Preclinical jockeying on the translational track of adenosine A2A receptors
- Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
- Structure-based and fragment-based GPCR drug discovery
- Adenosine A(2A) Receptor Antagonists and Parkinson's Disease
- Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors
- Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation
- Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases.
- In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease.
- The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates
- Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease
- In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease.
- Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design.
- A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.
- In vitro pharmacological profile of the A2A receptor antagonist istradefylline.
- Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
- Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships
- Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease
- Synthesis and in vivo Evaluation of Fluorine-18 and Iodine-123 Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as PET and SPECT Radiotracers for Mapping A2A Receptors.
|
| is cites work
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)